443798-55-8 Usage
Uses
Used in Cancer Therapy:
CDK1/2 Inhibitor III is used as an anticancer agent for its ability to selectively inhibit CDK1 and CDK2, which are key regulators of the cell cycle. This selective inhibition can effectively block the growth of various human tumor cells and has potential applications in treating different types of cancer.
Used in Cell Cycle Regulation Research:
CDK1/2 Inhibitor III is used as a research tool to study the role of CDK1 and CDK2 in cell cycle regulation. Its high potency and selectivity make it a valuable compound for investigating the mechanisms of cell cycle progression and identifying potential therapeutic targets for cancer treatment.
Used in Drug Discovery and Development:
CDK1/2 Inhibitor III serves as a lead compound in the development of new drugs targeting CDK1 and CDK2 for cancer therapy. Its properties can be further optimized to improve potency, selectivity, and pharmacokinetics, leading to the discovery of more effective and safer anticancer drugs.
Biochem/physiol Actions
Cell permeable: yes
Check Digit Verification of cas no
The CAS Registry Mumber 443798-55-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,3,7,9 and 8 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 443798-55:
(8*4)+(7*4)+(6*3)+(5*7)+(4*9)+(3*8)+(2*5)+(1*5)=188
188 % 10 = 8
So 443798-55-8 is a valid CAS Registry Number.
443798-55-8Relevant academic research and scientific papers
1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: Synthesis and evaluation of biological activities
Lin, Ronghui,Connolly, Peter J.,Huang, Shenlin,Wetter, Steven K.,Lu, Yanhua,Murray, William V.,Emanuel, Stuart L.,Gruninger, Robert H.,Fuentes-Pesquera, Angel R.,Rugg, Catherine A.,Middleton, Steven A.,Jolliffe, Linda K.
, p. 4208 - 4211 (2007/10/03)
A series of 1-acyl-1H-[1,2,4]triazole-3,5-diamine analogues were synthesized as cyclin-dependent kinase (CDK) inhibitors. These compounds showed potent and selective CDK1 and CDK2 inhibitory activities and inhibited in vitro cellular proliferation in various human tumor cells. Representative compound 3b demonstrated in vivo efficacy in a human melanoma A375 xenograft model in nude mice.
